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CORRELATION BETWEEN CT AND PATHOLOGICAL FINDINGS  IN LUNG 
ADENOCARCINOMA 
 
ABSTRACT 
 
The aim of this retrospective study was to determine CT appearance of 38 lung nodules that 
underwent CT-guided biopsies for cytological and/or histological evaluation. At biopsy all 
these lesions resulted lung adenocarcinoma. Unenhanced and contrast-enhanced CT 
examinations and CT-guided biopsies of all lesions were performed by using a 64-channels 
CT and a high definition 64-channels CT at Radiology Department of University of Pisa 
between June and December 2013. By using radiological criteria, the new 2011 
adenocarcinoma classification was applied to characterize these 38 lesions in the 
adenocarcinoma spectrum. CT characteristics of the nodules (nodule presentation, size, 
location and number) were registered by using the PACS system. According to the new 
classification the results were: one preinvasive lesions (AIS), two minimally invasive lesions 
(MIA) and 35 invasive lesions. A better application of the new lung adenocarcinoma 
classification both by the pathologists and the radiologists will allow an improved definition 
of the lesions in the adenocarcinoma spectrum, from premalignant to frankly invasive lesions 
which necessitate different ways of management.  
 
 
.  
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INTRODUCTION 
1.1.  General concepts and epidemiology 
Lung cancer is the most frequent cause of major cancer incidence and mortality worldwide1 . 
Classically, non small cell cancer (NSCLC), is subdivided into squamous cell carcinoma, 
adenocarcinoma and large cell carcinoma as major subtypes2. 
Adenocarcinoma is the predominant subtype, accounting for almost half of all lung cancers 
today, and its incidence has been reported to be increasing  worldwide over the past few 
decades. This rising prevalence has led to an evolution in our understanding of lung 
adenocarcinoma and related  lesions,  many of which appear as ground glass opacities 
(GGOs) on chest CT3. 
1.2 Previous pathologic classifications of adenocarcinoma of the lung 
One of the most import studies on pulmonary adenocarcinoma was published by Noguchi et 
al. in 1995, in which they categorized small pulmonary adenocarcinomas into six groups 
based on histology. In their study, patients patients with bronchiololalveolar carcinoma 
(BAC) (type A) and BAC with foci of collapsed alveolar structures (type B) had a better 5-
yaer survival rate (100%) than patients with BAC with a foci of active fibroblastic 
proliferation (type C, 75% of survival rate ) or patients with pure adenocarcinoma (type D-F, 
52% survival rate ).  
Because this classification proved to have good correlation with prognosis, in 1999 the World 
Health Organization (WHO) revised the classification of BAC as a noninvasive carcinoma, 
with no evidence of stromal, vascular or pleural invasion. Then, in the 2004 WHO 
classification, the term “mixed subtype adenocarcinoma” was introduced for tumors with 
invasion in association with a portion of the tumor having a  replacement or lepidic growth 
pattern3 .    
 4
The 1999/2004 WHO histological classification of lung tumors was created by pathologists 
with a special interest in thoracic oncology and mainly based on large, surgically resected 
specimens. The different adenocarcinoma subgroups of this classification are listed in table I.  
          Adenocarcinoma mixed subtype 
          Bronchioloalveolar carcinoma (BAC) 
                Nonmucinous 
                Mucinous 
                Mixed or indeterminate 
          Acinar adenocarcinoma 
          Papillary adenocarcinoma 
          Solid adenocarcinoma with mucin production 
          Variants: 
                Fetal adenocarcinoma 
                Mucinous (colloid) adenocarcinoma 
                Mucinous cystadenocarcinoma 
                Signet ring adenocarcinoma 
                Clear cell adenocarcinoma 
Of particular interest is bronchiolalveolar carcinoma (BAC) which was defined as a 
noninvasive tumor growing along pre-existing alveolar structures not penetrating the basal 
membrane regardless of size. In addition, a nonmucinous as well as mucinous and mixed type 
exists. In daily clinical practice this particolar subcatergory gave rise to much confusion as 
different lesions were considered to be BAC ranging from smaller ground-glass opacities 
(GGO) to large tumors invading almost an entire lobe, the so called pneumonic variant of 
BAC.  Moreover, a precise radiologic correlation and a size limit were no available. Altough 
different subtypes of adenocarcinoma exist, more of 70% of the resected adenocarcinomas 
belonged to the so called “mixed” subtype without further specification. To more adequately 
describe these tumors, a clear need was felt to refine classification. Moreover, as only about 
30% of lung cancers undergo surgical resection, an adequate description of pathological 
information which may be obtained from smaller biopsies and cytology specimens, was also 
considered necessary 2. 
Table I. Lung adenocarcinoma subtypes of the 1999/2004 World Health Organization (WHO) 
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1.3 New 2011 IASLC/ATR/ERS classification 
Because of the  previously mentioned reasons, a common working group for the classification 
of adenocarcinoma was created  by the International Association for the study of Lung Cancer 
(IASLC), American Thoracic Society  (ATS) and European Respiratory Society (ERS). For 
the first time this consisted of a large, multidisciplinary group incorporating not only 
pathologists but also dedicated pulmonary physicians, oncologists, molecular biologists, 
radiologists and thoracic surgeons. Clinical correlates and implications were discussed 
resulting  not only  in development of clear recommendations but also of topics for further 
research.   
The newly introduced adenocarcinoma classification proposed a new approach to diagnosis in 
non-resection specimens (small biopsies and cytology) which is applicable to the majority of 
lung cancer patients who present with advanced disease (listed in Table II), but  the aspect of 
the classification that addresses resection specimens (listed in Table III) is the most important 
for surgical oncologists. Its specific advantages are listed in Table IV2.  
Unlike previous WHO classifications, where the primary diagnostic criteria for as many 
tumor types as possible were based on hematoxilin and eosin (H&E) examination, the 
classification emphasizes the use and integration of immunoistochemical (i.e., thyroid 
trascription factor [TTF-1]/p63 stainings), histochemical (i.e., mucin staining) and molecular 
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studies as specific therapies are driven by histologic subtyping. 
 
Table II. Proposed  IASLC/ATS/ERS classification for small biopsies/cytology. 
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Preinvasive lesions 
  Atypical adenomatous hyperplasia 
  Adenocarcinoma in situ (< 3 cm, pure lepidic growth without invasion, formerly 
BAC) 
  Nonmucinous 
   Mixed mucinous/nonmucinous 
Minimally invasive adenocarcinoma (<3 cm lepidic predominant tumor with 
<5mm invasion) 
  Nonmucinous 
  Mucinous 
  Mixed mucinous/nonmucinous 
Invasive adenocarcinoma 
   Lepidic predominant (formerly nonmucinous BAC pattern, with >5mm 
invasion) 
   Acinar predominant 
   Papillary predominant 
   Micropapillary predominant 
   Solid predominant with mucin production 
Variants of invasive adenocarcinoma: 
   Invasive mucinous adenocarcinoma (formerly mucinous BAC) 
   Colloid 
   Fetal (low and high grade) 
   Enteric 
 
 
Multidisciplinary approach 
Surgical specimens and small biopsies addressed 
Disappearance of confusing BAC subtype 
Distinction pre‐invasive, minimally invasive and invasive lesions 
Comprehensive, semiquantitative subtyping 
Correlation imaging characteristics 
Impact on treatment, more personalized therapy 
Judicious use of immunohistochemical and molecular markers 
Addresses multiple primary tumors 
 
 
Altough these techniques should be used whenever possible, it is recognized that this may not 
always be possible, and thus, a simpler approach is also provided when only H&E-stained 
slides are available, so this classification may be applicable even in a low resource setting1.  
 
Table III. Classification of lung adenocarcinoma in resection specimens.  
Table IV. Advantages of the 2011 lung adenocarcinoma classification.  
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In the IASSL/ATS/ERS adenocarcinoma classification a clear distinction is made between 
pre-invasive lesions (Atyppical adenomatous Hyperplasia, AAH and Adenocarcinoma in Situ, 
AIS), minimally invasive lesions (Minimally Invasive Adenocarcinoma, MIA) and invasive 
adenocarcinomas (see Table III).  The term BAC is not used anymore2. Categories of the new 
classification  where the former term BAC was applicable are listed in Table V. 
1. Adenocarcinoma in situ (AIS), which can be nonmucinous and rarely 
mucinous 
2. Minimally invasive adenocarcinoma (MIA), which can be nonmucinous 
and rarely mucinous 
3. Lepidic predominant adenocarcinoma (nonmucinous) 
4. Adenocarcinoma, predominantly invasive with some nonmucinous 
lepidic component (includes some resected tumors, formerly classified 
as mixed subtype, and some clinically advanced adenocarcinomas 
formerly classified as nonmucinous BAC) 
5. Invasive mucinous adenocarcinoma (formerly mucinous BAC) 
 
 
Atypical Adenomatous Hyperplasia (AAH), a premalignant lesion already recognized in the 
1999/2004 WHO classification, is a localized, small (usually 5 mm or less) proliferation of 
mildly to moderately atypical type II pneumocytes and/or Clara cells lining alveolar walls and 
sometimes respiratory bronchioles (Figures 1A, B).  
 
 
 
  
 
 
 
 
Table V. Categories of the new adenocarcinoma classification where former BAC concept 
was used.  
Figure 1. Atypical  adenomatous hyperplasia. A. This 3 mm nodular lesion consists of 
atypical pneumocytes proliferating along preexisting alveolar walls. B. The slightly atpical 
pneumocytes  are cuboidal and show gaps between the cells. Nuclei are hyperchromatic, 
and a few show nuclear enlargement and multinucleation.  
 
 9
Adenocarcinoma In Situ (AIS) is a newly introduced preinvasive lesion. It is a localized small 
(<3 cm) adenocarcinoma with growth restricted to neoplastic cells along preexisting alveolar 
structures (lepidic growth), lacking stromal, vascular or pleural invasion1. Almost all cases of 
AIS are non-mucinous, consiting of type II and/or Clara cells (Figures 2 A, B). Rare cases of 
mucinous AIS exist.  When completely resected, AIS should have 100% disease-specific 
survival. AIS is one of the lesions formerly known as BAC.  
 
 
 
 
 
 
 
 
 
Minimally Invasive adenocarcinoma (MIA) is a newly introduced small solitary 
adenocarcinoma (<3 cm), with a predominantly lepidic pattern and <5 mm invasion in 
greatest dimension in any one focus. The invasive component to be measured in MIA is 
defined as presence of histologic subtypes other than lepidic pattern or tumor cells infiltrating 
myofibroblastic stroma. MIA is excluded  if the tumor invades lymphatics, blood vessels or 
pleura, or contain tumor necrosis. If multiple microinvasive areas are found in one tumor, the 
size of the largest invasive area should be measured in the largest dimension, and it should be 
< 5 mm. MIA is usually nonmucinous (Figure 3A, B) but rarely may be nonmucinous. 
Figure 2. Nonmucinous adenocarcinoma in situ. A, This circumscribed nonmucinous 
tumor grows purely with a lepidic pattern. No foci of invasion or scarring are seen. 
 B, The tumor shows atypical pneumocytes proliferating along the slightly thickened, 
but preserved, alveolar walls 
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Patients  with MIA should have a near 100% disease-specific survival, if completely resected. 
1,2
 
 
 
  
 
 
 
 
 
 
Invasive adenocarcinoma represent more than 70 to 90% of surgically resected lung cases. As 
these tumors are composed of a complex heterogenoeus mixture of histologic subtypes, 
histologic patterns are described semiquantitatively in 5% increments and at the same time a 
single predominant pattern is determined. Semiquantitative recording of the patterns in 5% 
increments yields the advantages that all subtypes are listed and that the main component is 
also identified. Moreover comprehensive histologic subtyping can be useful in comparing 
multiple lung adenocarcinomas to distinguish multiple primary tumors from intrapulmonary 
metastases.  
The major histologic patterns are: lepidic predominant adenocarcinoma (LPA), acinar 
predominant adenocarcinoma, papillary predominant adenocarcinoma, micropapillary 
predominant adenocarcinoma, solid predominant adenocarcinoma with mucin production.  
Lepidic predominant adenocarcinoma (Figure 4 A,B) consists of type II pneumocytes or 
Clara cells growing along the surface of alveolar walls associated with at least one focus of 
 
Figure 3. Nonmucinous minimally invasive adenocarcinoma. A, This adenocarcinoma 
consists primarly of lepidic growth with a central scar which is mostly benign with 
small foci of invasion at the edges of the scar (<0,5 cm) area of invasion. B, From the 
area of invasion, these acinar glands are invading the fibrous stroma.  
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invasion measuring more than 5 mm in greatest dimension. Invasion is defined as: (1) 
histological subtypes other than lepidic pattern (i.e., acinar, papillary, micropapillary  and/or 
solid) or (2) myofibroblastic stroma associated  with invasive tumor cells. The diagnosis of 
LPA rather than MIA is made if the tumor invades lymphatics, blood vessels or pleura or 
contain tumor necrosis.  
 
 
         
  
 
 
 
 
 
Acinar  predominant adenocarcinoma (Figure 5A) shows a majority component of glands 
which are round to oval shaped with a central luminal space surrounded by tumor cells 
invading the myofibroblastic stroma. The neoplastic cells and glandular spaces may contain 
mucin. Acinar structures also may consist of rounded aggregates of tumor cells with 
peripheral nuclear polarization with central cytoplasm without a clear lumen.  
Papillary predominant adenocarcinoma (Figure 5B) shows  a major component of a growth  
of cuboidal to columnar glandular cells along central  fibrovascular cores.  
Micropapilllary predominant adenocarcinoma (Figure 5C) has tumor cells growing in 
papillary tufts, which lacks fibrovascular cores. The tumor cells are usually small and 
cuboidal with minimal nuclear atypia.  
Figure 4. A, Lepidic predominant pattern with mostly lepidic growth (right) and a 
smaller area of invasive acinar adenocarcinoma (left). B, Lepidic pattern consists of 
a proliferation of  type II pneumocytes and Clara cells along the surface of alveolar 
walls.  
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Solid  predominant adenocarcinoma  with mucin production (Figure 5D) shows a major 
component of polygonal tumor cells forming sheets, which lack recognizable patterns of 
adenocarcinoma, i.e., acinar papillary or lepidic growth. If the tumor is 100% solid, 
intracellular mucin should be present in at least five tumor cells in each of two high-power 
fields, confirmed with histochemical stains for mucin.  
Histologic variants recognized in the new classification are: invasive mucinous 
adenocarcinoma, colloid adenocarcinoma, fetal adenocarcinoma and  enteric adenocarcinoma.  
Invasive mucinous adenocarcinoma (formerly mucinous BAC) has a distinctive histologic 
appearance with tumor cells having a goblet or columnar cell morphology with abundant 
intracytoplasmic mucin. These tumors may show the heterogeneous mixture of lepidic, acinar,  
papillary, micropapillary, and solid growth as in nonmucinous tumor. 
Colloid adenocarcinoma shows extracellular mucin in abundant pools, which  distend 
alveolar spaces with destruction of their walls. The mucin pools contain clusters of mucin-
secreting tumor cells,  consinsting of goblet cells or other mucin secreting cells.  Colloid 
adenocarcinoma is found more often as a mixture with other adenocarcinoma histologic 
subtypes than as a pure pattern.  
Fetal adenocarcinoma consists of glandular elements with tubules composed of glicogen-rich 
noncliated cells that resemble fetal lung tubules. Subnuclear vacuoles are common and 
characteristic. Squamoid morules may be seen within lumens. Most are low grade with a 
favourable outcome. High grade tumors occur.  
Enteric adenocarcinoma consists of glandular and/or papillary structures sometimes with a 
cribiform pattern lined by tumor cells that are mostly tall-columnar with nuclear 
psuedostrtification, luminal necrosis and prominent nuclear debris.  The enteric pattern shares  
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morphologic features with colorectal adenocarcinoma. Moreover these tumors show at least 
one immunohistologic marker of enteric differentiation (CDX-2, CK20, or MUC2) 1.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Columnar with nuclear pseudostrtification, luminal  
1.5 Small biopsies and cytology: immunoistochemical and molecular profiling. 
The prognosis of lung cancer remains dramatically poor, as nearly 75% of NSCLC patients 
have unresectable advanced disease at the time of diagnosis. Therefore, radiotherapy and 
chemotherapy with conventional cytotoxic agents were the only therapeutic approaches, until 
the discovery of “driver” oncogenic mutations (e.g. EGFR mutations) in a subset of lung 
tumors. This led to the subsequent development of corresponding targeted therapies4.  
Figure 5. A, Acinar adenocarcinoma composed of round to  oval shaped malignant glands 
invading a fibrous stroma, B, Papillary adenocarcinoma consists of malignant cuboidal to columnar 
tumor cells growing on the surface of fibrovascular cores. C, Micropapillary adenocarcinoma 
consists of small papillary clusters of glandular cells growing within the airspace, most of  which 
do not show fibrovascular cores. D, Solid adenocarcinoma  with mucin consiting of sheets of tumor 
cells with abundant cytoplasm and mostly vesicular nuclei with several conspicuous nucleoli. 
Multiple cells have intracytoplasmatic basophilic globules that suggest intracytoplasmatic mucin. 
 14
Because of the need for improved separation of squamous cell carcinoma from 
adenocarcinoma, as it determines eligibility for molecular testing and impacts on specific 
therapies, there is now greater clinical interest  in application of additional pathology tools 
(immunohistochemical stains, molecular studies) to refine further the diagnosis in small 
biopsies (bronchoscopic, needle, or core biopsies) and cytology specimens from patients with 
advanced lung cancer, when morphologic features are not clear. The diagnosis should be 
recorded in a manner making clear if it is based on light microscopy alone or light microscopy 
plus special studies.  Patients with adenocarcinoma should be tested for EGFR mutations 
because patients with EGFR mutation-positive tumors may be eligible for first-line tyrosine-
kinase inhibitors (TKI) therapy (erlotinib, gefitinib). Adenocarcinoma patients are also 
eligible for pemetrexed or bevacizumab-based chemotherapy regimens1. Strategic use of 
small biospsy and cytology sample is important, i.e., use the minimum specimen necessary 
for an accurate diagnosis, to preserve as much tissue as possible for potential molecular 
studies. Squamous cell carcinoma and adenocarcionoma should be diagnosed on biopsy and 
cytological materials when the criteria for specific diagnosis of these tumor types in the 2004 
classification are met. Nevertheless, for tumors that do not meet these criteria, new 
terminology and criteria are proposed  in the  2011 IASLC/ATR/ERS classification (see table 
II and figure 6) 1.  
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Figure 6 Algorithm of the 2011 IASLC/ATR/ERS classification for the diagnosis of  
adenocarcinoma and squamous cell carcinoma in small biopsies and/or cytology. 
(-ve = negative; +ve = positive; IHC, immunochemistry; NE, neuroendocrine; CK, cytokertatin;  
EGFR, epidermal growth factor receptor). 
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When positive biopsies (fiber-optic bronchoscopy [FOB], transbrochial, [TTBx], core or 
surgical lung biopsy [SLBx]) or cytology (effusion, apsirate, washings and brushings) show 
clear adenocarcinoma (ADC) or squamous cell carcinoma (SQCC) morphology, the diagnosis 
can be firmly estabilished.  
Whenever possible, cytology should be used in conjunction with histology in small biopsies 
to achieve the most  specific and nondiscordant diagnoses. 
Because of histologic heterogeneity, small biopsy and/or cytology samples may not be 
representative of the total tumor, and there may be a discrepancy with the final histologic 
diagnosis in a resection specimen.  
The terms AIS or MIA should not be diagnosed in small biopsies or cytology specimens. If a 
non-invasive pattern is present in a small biopsy it should be referred to as a lepidic growth 
pattern. 
If there is neuroendocrine morphology, the tumor may be classified as small cell carcinoma 
(SCLC) or non small cell lung carcinoma  (NSCLC), probably large cell neuroendocrine 
carcinoma (LCNEC) assessing the NE immunohistochemical markers (CD56, chromogranine 
an/or synaptophysin).  
If there is no clear ADC or SQCC morphology, the tumor is regarded as NSCLC–not 
otherwise specified (NOS). The NSCLC-NOS can be further classified on: (a) 
immunonohistochemical stains, (b) mucin (diastase-periodic acid Schiff [DPAS] or 
mucicarmine) stains or (c) molecular data.  At present time, throyroid transcription factor 1 
(TTF-1), seems to be the best marker for adenocarcinoma. TTF-1 is useful as a pneumocyte 
marker that can help confirm a primary a primary lung origin in 75% to 85% of  lung 
adenocarcinoma. This can be very helpful in addressing the question of metastatic 
adenocarcinoma from other sites such as the colon or breast. 
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If  ADC markers (i.e., TTF-1 and/or mucin ) are positive with negative SQCC markers, the 
tumor is classified as NCLC, favor ADC (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If SQCC markers (i.e, p63 and cytokeratin 5/6 [CK5/6]) are positive with negative ADC 
markers, the tumor is classified as NSCLC, favor SQCC. 
If the ADC and SQCC markers are both strongly positive in different population  of tumor 
cells, the tumor is classified as NSCLC-NOS, with a comment it may represent 
adenosquamous carcinoma. If all markers are negative, the tumor is classified as NSCLC-
NOS.  
Tumors with sarcomatoid features, such as marked nuclear pleomorphism, malignant giant 
cells, or spindle cell morphology, should be preferentially regarded as adenocarcinoma or 
Figure 7. Adenocarcinoma in small biopsy and cytology. Poorly differentiated non-small 
cell carcinoma, favor adenocarcinoma. A, core biopsy showing a solid pattern of growth 
without any acinar, papillary or lepidic patterns. The mucin stain was negative. B, The 
TTF-1 stain is strongly positive. C, the p63 stain is very focally positive. The strongly and 
diffusely positive TTF-1 and only focal p63 staining favor adenocarcinoma. EGFR 
mutation was positive. D, cytology from different adenocarcinoma shows large malignant 
cells with abundant cytoplasm and prominent nuclei growing in an acinar structure.  
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squamous cell carcinoma if clear glandular or squamous features are present.  If such features 
are not present, the term “poorly differentiated non-small cell carcinoma with giant and/or 
spindle cell features” should be used.  
EGFR testing should be performed in: (1) classic ADC, (2) NSCLC, favor ADC, (3) NSCLC-
NOS, (4) NSCLC-NOS, possible adenosquamous carcinoma.  
If tumor tissue is inadequate for molecular testing, there may be a need to rebiopsy the patient 
to perform testing that will guide therapy. 
1.4 Genetic abnormalities targeted by specific therapies 
The recent development of personalized therapies requires individual tumor molecular 
profiling, which can be achieved on most small size specimens. Mutations of EGFR, KRAS, 
and EML/ALK rearrangements are the most frequent genetic abnormalities in lung 
adenocarcinomas and are mutually exclusive. 
 These activating mutations or translocation of growth promoting oncogenes are responsible 
for a permanent tyrosine kinas activation.  
EGFR mutations/deletions and ALK rearrangements are specifically targeted by inhibitors 
currently used. 
The most common EGFR mutations result in an arginine for leucine substitution at amino 
acid 858 and in-frame deletions at exon 19. EGFR mutations are specifically targeted by 
tyrosin kinase inhibitors (TKIs) such as  erlotinib and gefitinib.  
Increased number of copies of EGFR gene has been correlated with high histology grade of 
the tumor and with its invasiveness.  
KRAS mutations have been identified in patient with NSCLC  more than 20 years ago, but 
their clinical role as biomarkers for response to therapy and prognosis remain controversial. 
KRAS mutations are strongly correlated with invasive mucinous adenocarcinoma 
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Mutations of  EGFR and KRAS can be found with a frequency of 10 to 30 % each in 
preinvasive lesions, MIA and invasive adenocarcinoma.  
EGFR mutation frequency is higher in Asians, never smokers and nonmucinous tumors, while 
KRAS mutations are most common in non-Asians, smokers and in invasive mucinous 
adenocarcinoma.  
Mutations of another oncogene, p53 can be found in invasive adenocarcinoma. 
The EMLK/ALK translocation leads to an oncogenic constitutive activation of AKL by the 
dimerization of the fusion protein, specifically targeted by crizotinib, an inhibitor of MET and 
ALK. Adenocarcinoma and other histological types such as SQCC contain EML4-ALK 
translocation. 
There may be important differences between the primary tumor and metastases of lung 
adenocarcinoma both with respect to morphology and biomarker expression; in particular the 
mutation status of metastases can be the same or different from that  of the primary tumor and 
also among metastases.  
Several prior studies have shown that cytology specimens, particularly cellblocks from fine 
needle aspirates (FNAs), were highly suitable for EGFR (and KRAS) mutation analysis. 
Small  biopsies including trans-thoracic needle core biopsy (TTNB) and FNA in routine 
practice could be potentially useful , even if TT biopsy and aspiration both belong to the same 
site of sampling4. 
Recently, investigators have noted that all NSCLC histologies other than squamous cell 
carcinioma seems to garner benefit from two drugs, pemetrexed (a multitarget  antifolate 
agent) for efficacy,  and bevacizumab (a VEFG-specific monoclonal antibody) for avoidance 
of toxicity. Indeed, patients with squamous cell carcinoma assuming  bevacizumab  are at 
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greater risk of adverse events such as pulmonary hemoorrage, and therefore, such patients 
have been excluded from receiving this drug by the Food and Drug Administration.   
1.5 Prognostic factors and grading of adenocarcinoma 
Multiple clinical, pathologic and molecular factors have been explored for their association 
with patient outcome. The main independent clinical prognostic factors  for patients with lung 
adenocarcinoma are stage, performance status, age and sex. The independent prognostic value 
of stage exists whether using clinical or pathological staging. Data also suggest that smoking 
history may be an independent prognostic factor.  
Only a few studies have evaluated detailed morphologic grading systems; nevertheless the 
following histologic features are promising candidates for components of a grading system. 
The primary approaches are based on architectural and/or nuclear attributes.. By architecture, 
the following prognostic associations have been reported: poor (solid and micropapillary), 
favorable (nonmucinous lepidic [formerly BAC]), and intermediate (papillary and acinar). 
Thus, comprehensive histologic subtyping method and subclassification of invasive tumors by 
the predominant subtype, may be a simple way to develop the architectural grade of lung 
adenocarcinoma. By nuclear criteria, preliminary data suggest poor prognosis may be 
associated with large nuclei and variability in nuclear size and shape.  
Tumors with minimal solid component have worse prognosis than those without solid 
component.  
Tumors expressing EGFR mutations have better prognosis. In fact there is a suggestion that 
patients who underwent surgical resection for lung adenocarcinoma that have EGFR 
mutations seem to have better prognosis in the absence of EGFR-TKI therapy than those 
without, based on two retrospective observational studies. 5,6 
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2.1 TNM Staging 
The 7th edition  of the Tumor, Node and Metastasis staging manual (TNM-7) for lung cancer  
incorporates changes to the previous system of staging of NSCLC (TNM-6) that were 
recommended by the International Association for the Study of Lung Cancer (IASLC) to 
improve the prognostic relevance of its descriptors. These recommendations were made on 
the basis of a rigorous retrospective survival analysis of a database composed of 67.725 
patients with NSCLC from 19 countries in four continents; all data underwent robust internal 
and external validation. The T, N and M descriptors of the new classification  are presented in 
Figure 8. Factors that implied the need for revision of the staging system were the followings: 
the shifting prevalence of the various histologic subtypes of NSLLC, with increasing 
prevalence of adenocarcinoma in recent decades; advances in staging techniques, with large 
use of multidetector CT and PET/CT, and in therapeutic strategies; new evidence from other 
databases which suggests that the survival rate for each of the TNM-6 stages overlap with one 
another.  Changes to TNM-7 include subdivision of T1 and T2 disease according to size cut 
points; reassignment of the T and M categories of same-lobe, ipsilateral, and contralateral 
malignant pulmonary nodules; reassignement of pleural disease to metastatic disease (Table 
VI); and introduction of intrathoracic and extrathoracic metastatic disease (Table VII). 
Because of movement between T and M descriptors and resultant stage migration, new stage 
groupings containing TNM subsets different from those of TNM-6 were created.(Table VIII). 
The new classification has many advantages; however limitations remain. Problems with 
routine radiologic staging of NSCLC have not been addressed (e.g. no specific guidance is 
provided for the measurement of ill-defined, subsolid, cavitary or infiltrative lesions), the 
varied survival rates for patients with different histologic subtypes is not reflected, the new 
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classification is not compatible with the previous system, and application of treatment 
algorithm on the basis of evidence from the previous edition is less clear.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary tumor (T) 
-T1: tumor < 3 cm in diameter, surrounded by lung or visceral pleura, without invasion 
more proximal than lobar bronchus. 
-T1a: tumor <2 cm in diameter. 
-T1b: tumor >2 cm but < 6 cm in diameter. 
-T2: tumor >3 cm but  < 7 cm in diameter or tumor with any of the following features: 
involvement of the main bronchus > 2 cm distal to the carina; invasion of visceral pleura; 
associated atelectasis or obstructive pneumonitis that does not involve the entire lung. 
-T2a: tumor < 5 cm in diameter. 
-T2b: tumor >5 cm but <7 cm in diameter. 
-T3: tumor >7 cm in diameter, or tumor with any of the following features:  
direct invasion of the chest wall, diaphragm, phrenic nerve; direct invasion of mediastinal 
pleura or parietal pericardium; associated atelectasis or or obstructive pneumonitis of the 
entire lung; tumor within the main bronchus <2 cm to the carina, without involvement of 
of the carina; 
satellite tumor nodules in the same lobe; 
T4: tumor of any size that has the following features:  
Invasion of the mediastinum; invasion of the heart or great vessels; invasion of the 
trachea, oesophagus or recurrent laryngeal nerve; invasion of a vertebral body or carina; 
separate tumor nodules in a different ipsilateral lobe 
 
 
Regional lymph nodes (N) 
-N0: no regional lymph node metastasis. 
-N1: involvement of ipsilateral hilar or peri-bronchial nodes. 
-N2: involvement of ipsilateral mediastinal or subcarinal nodes. 
-N3: involvement of contralateral mediastinal or hilar nodes, or involvement of ipsilateral 
/contralateral scalene or supraclavicular nodes. 
 
 
Distant Metastasis (M) 
-M0: no distant metastasis 
-M1: distant metastasis present  
-M1a: separate tumor nodule(s) in a contralateral lobe or tumor with pleural nodules or 
malignant pleural/pericardial effusion. 
-M1b: distant metastases.  
 
 
Figure 8: TNM descriptors in the 7th edition of the TNM staging of Non-Small Cell 
Lung Cancer.  
 23
 
The limitations of applying TNM-7 guidelines to some histologic tumor subtypes are evident 
when considering the spectrum of atypical adenomatous hyperplasia, bronchioloalveolar 
carcinoma and mixed subtype invasive adenocarcinoma with some features of 
bronchioloalveolar carcinoma. Bronchioloalveolar carcinoma accounts for 2-6% of cases of 
NSCLC, 25% of which are multifocal. Detection of multifocal adenomatous hyperplasia and 
bronchiolveolar carcinoma largely depends on CT technique; rapid acquisition thin-section 
multidetector CT has increased sensitivity for the detection of these tumors, which 
demonstrate pure ground-glass and mixed attenuation. These tumors also have doubling times 
much longer than those of other solid primary tumors: Adenomatous hyperplasia has a mean 
doubling time of 988 days, and mixed subtype invasive adenocarcinoma with features of 
bronchiolalveolar carcinoma has a mean doubling time of 384 days. In addiction, in  patients 
with these types of tumors, multifocal lesions have less than an effect on survival than they do 
in patients with non-bronchioloalveolar carcinoma.  
Altough it is not recognized in any of the TNM staging manuals, CT plays an integral role in 
the evaluation of patients with single or multifocal lesions within the spectrum of 
adenomatous hyperplasia and bronchioloalveolar carcinoma. The extent of ground-glass 
attenuation within a bronchioloalveolar carcinoma lesion correlates well with the Noguchi 
histologic classification of these lesions and their malignant potential. In practice, serial long-
term follow-up may be necessary to detect any increase in overall size or in the solid portion 
of subsolid lesions, signs of disease progression. CT may be used to plan limited localized 
resection (rather than lobectomy), which substantially affects morbidity and quality of life in 
these patients. 
 24
Despite its downstaging of same-lobe nodules from T4 to T3 and of ipsilateral lung nodules 
from M1 to T4, the TNM-7 system does not accurately reflect prognosis of patients with 
lesions within the bronchiololalveolar carcinoma and adenocarcinoma spectrum and it may 
unnecessarily upstage cases, particularly those with multifocal bronchiololveolar carcinoma 
with foci of bronchiololveolar carcinoma in the controlateral lung, which may be classified as 
stage IV disease.  
The new staging system is a substantial improvement over the previous system and is the first 
major revision to the TNM classification of NSLC in 12 years, during which substantial 
changes in understanding tumor behaviour, approaches to treatment and advances to clinical 
staging have occurred. However, because of methodological issues, the new TNM staging  
system does not reflect all these changes, nor does it address many of  the  persistent imaging 
issues encountered during the staging of lung cancer.  
Prospective analyses are planned to address these limitations, and it is hoped that future 
iterations of the TNM staging system will address many of these issues and provide guidance 
and uniformity to these staging dilemmas7 .  
 
 
 
 
 
 
 
 
 
Table VI: Survival rates associated with various pathologically staged T descriptors in 
TMN-6 and their corresponding TNM-7 designations.  
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Table VII: Median survival associated with clinically staged T and M descriptors in 
TNM-6 and their corresponding TNM-7 designations.  
 
Table VIII: New stage groupings and  consequent stage migration from TNM-6 to TNM-7 
Figure 9: Low-grade 
bronchioloalveolar carcinoma in 
a 53-year –old man with no 
history of smoking. Axial contrast  
CT image (section thickness 1,25 
mm), obtained with lung window 
settings , shows a focal nodule 
with pure groundd glass 
attenuation with vasculature 
within. 
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2.2 Radiologic terminology of the CT appearance of lung adenocarcinoma 
Examining the appearance of lung adenocarcinoma at CT imaging, it is necessary to introduce 
some terms, largely based on the Fleischner Society glossary of terms and the suggested 
guidelines by Godoy and Naidich for subsolid nodules8. 
Nodule on a CT s   can is defined as a rounded or irregular opacity, well or poorly defined, 
measuring up to 3 cm in greatest diameter in any plane. If the opacity is greater than 3 cm, it 
is referred to as a mass.  
A non solid nodule (also termed ground glass nodule, GGN) is a focal area of increased lung 
attenuation within which the margins of any normal structure, e.g. , vessels, remain outlined.  
A solid nodule is a focal area of increased attenuation of such density that normal structures, 
e.g., vessels, are completely obscured.  
Figure 10: Invasive adenocarinoma (mixed subtype) in a 67 year-old woman 
with a history of smoking. Axial contrast-enhanced CT image (section 
thickness, 1,25), obtained with lung window settings shows a mixed-
attenuation lesion with a large central solid component surrounded by a 
peripheral area of ground-glass attenuation.. A computer-aided detection 
(CAD) alghoritm was used to depict the margins of the tumors. CT, and 
possibly CAD, is used to monitor the size and solid portion of tumors-
characteristics not included in TNM-7-in patients with tumors within the 
adenocarcinoma-bronchioloalveolar carcinoma spectrum.  
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A part solid nodule (also termed semisolid nodule) represents a focal nodular opacity 
containing both solid and ground-glass components.  
The term subsolid nodule refers to both part-solid nodules and pure GGN.  
Optimal evaluation of subsolid nodules requires thin-section CT scans  (< 3 mm thickness) to 
assess the solid versus ground-glass components1.  
2.3 Radiologic implications of the new 2011 classification of  adenocarcinoma of the lung 
The new 2011 classification introduces two new important entities: Adenocarcinoma in situ 
(AIS) and Minimally Invasive Adenocarcinoma (MIA) (Table IX).  
AIS  refers to a purely lepidic (growth along alveolar walls ) and non-invasive tumor of 3 cm 
or smaller. If the lesion is resected, patients have 100% disease-free survival with respect to 
this tumor. The designation AIS is limited to 3 cm or smaller because data are not available 
concerning postresection disease-free survival for larger purely lepidic lesions. In addition, in 
the setting of adenocarcinoma that  have both an invasive component of larger than 5 mm and 
a non-invasive lepidic component, the histopatologic term lepidic is introduced to replace the 
old term BAC for the non-invasive lepidic component. 
AIS joins atypical adenomatous hyperplasia (AAH) under the category of preinvasive lesions 
for lung adenocarcinoma.  
AAH is usually a nodule of smaller than 5 mm and is minimally hazy, also called nonsolid or 
ground glass (Figure 11).  
Like AAH, AIS is not invasive histopatologically. At thin-section CT, AIS is usually a 
nonsolid nodule and tends to be slightly more opaque than AAH (figure 12). However, 
overlap exists among the imaging features of the preinvasive and minimally invasive lesions 
in the lung adenocarcinoma spectrum.  
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Moreover, as pathologists are in the early phase of learning how to apply the new 
International Association for the study of lung Cancer, American Thoracic Society, and 
European Respiratory Society classification system, there is room for improvement in 
reproducibility. A recent review9 of the new classification showed a moderate agreement for 
pulmonary pathologists and good to very good agreement after a training session.  
In the setting of adenocarcinomas that have both an invasive component and a non-invasive 
component, the histopathologic term lepidic is introduced to replace the old term BAC for the 
pattern of adenocarcinoma where tumor cells grow along the surface of alveolar walls. In this 
setting, the term lepidic was chosen rather than in situ, to avoid confusion with AIS. 
The other important new entity is MIA, which represents a 3 cm or smaller lepidic 
predominant adenocarcinoma with an invasive component of 5 mm or smaller (Figure 13). 
Few articles provide survival results according to these criteria, but currently available data 
suggest 5-year disease –specific survival is nearly 100% if complete resection is performed. 
MIA, which also represents one of the categories of the former BAC classification (Table III), 
is nearly always nonmucinous. For the rare mucin-producing form of the tumor, the mucin 
may contribute to a solid or part-solid appearance of the tumor at CT, and this diagnosis 
should be made with caution. For nonsolid nodules, shape does not appear to be a 
differentiating criterion between AIS and MIA. 
Size and shape of the solid component of MIA at thin-section CT remain to be described , but 
the solid component is likely to be in the range of up to approximately 5 mm in length (Table 
III).Because the histopathologic components of small adenocarcinomas of the lung can 
include alveolar collapse, inflammatory cells, fibroblasts, fibrosis, non-invasive lepidic 
cellular growth, and occasionally mucus, as well as invasive adenocarcinoma,, the size of the 
solid component may be expected to be larger at CT than the size of the actual invasive 
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adenocarinomatous component. When adenocarcinoma of the lung includes a component of 
non-invasive lepidic growth, the invasive portion of the cancer is characteristically solid at CT 
and the non-invasive lepidic component at CT is hazy and nonsolid (ground glass). 
Radiologically the solid component is to be considered as representing invasive growth, 
unless proved otherwise. Fibrotic scars may also contribute to the solid component of 
adenocarcinomas seen at CT. In most tumors, the size of this scar correlates with the degree 
of invasion; tumors with larger scars have a worse prognosis. 
Given the positive results of the National Lung Screening Trial10, it is possible to anticipate 
increased use of CT screening for lung cancer and a resultant increase in identification of 
early lesions such as AIS and MIA. Because these lesions are indolent, in clinical practice 
they should not be regarded as conventional invasive adenocarcinomas. 11 
 
 
 
 
 
 
 
 
 
 
 
 
Table IX. Classification of the spectrum of adenocarcinoma of the lung, 
involving the former term BAC.  
 30
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 11. AAH. Axial CT image shows a hazy 3-mm non solid nodule (arrow) in the 
right upper lobe, confirmed histopathologically as AAH. Frequently 5 mm or smaller, 
this entity is not invasive. 
Figure 12, AIS, formerly known as BAC. Contiguous axial CT images of the left 
upper lobe show (on the left) a nonsolid nodule that contains a few tiny sites of 
increased attenuation (arrow), which were of concern for possible focal 
microinvasion of MIA; however (on the right) the nodule is predominatly nonsolid. 
Because of imaging features of AIS and MIA can overlap, serial CT imaging is 
advised to search over time for increasing attenuation as an early sign of focally 
invasive adenocarcinoma.  
a b 
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2.3.1 Lepidic predominant adenocarcinoma 
The new classification also replaces the old term adenocarcinoma, mixed subtype (which 
applied to about 90% of invasive lung adenocarcinomas because of the frequent histologic 
heterogeneity of subtypes). Pathologists will now classify overtly invasive adenocarcinoma of 
the lung according to the predominant histologic subtype (acinar, papillary solid and lepidc), 
after performing comprehensive histologic subtyping in which the percentage of each 
histologic sutype is estimated in 5% increments. For example, overtly invasive 
adenocarcinomas with a lepidic predominant pattern and an invasive component of larger than 
5 mm will be classified as lepidic predominant adenocarcinoma (Figure 14).  
Figure 13 MIA. Axial (a) and coronal (b) CT images through the right upper lobe 
show a predominantly nonsolid nodule containing a solid component of less than 5 
mm (arrows). Only the solid portion represents invasive disease, while the 
nonsolid portions represent non-invasive disease of AIS. Postresection prognosis 
of MIA is as yet preliminarly described but approaches 100%. 
a  b 
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Micropapillary is also introduced as a new subtype and is associated with a less  favorable 
prognosis than other subtypes of adenocarcinoma of the lung. For example, among small (< 
20 mm) resected adenocarcinomas, the micropapillary subtype has been described as having 
5-year survival of 54%, compared with 81% for nonmicropapillary tumors.  
Growth rates for adenocarcinoma of the lung are not necessarily constant. A few cases have 
even been described in which follow-up CT examination showed slight decrease in volume of 
a tumor, presumably secondary to retraction caused by alveolar collapse and fibrosis. 
However, an alternate explanation for the observation may be simply measurement error that 
causes imprecision in quantifying small amounts of change of volume. 
An interesting recent observation for small (< 20 mm) adenocarcinoma of the lung is that a 
notch at CT, defined as a “concave” cut, appears to be a somewhat unfavourable prognostic 
sign: 5-year relapse-free survival of approximately 70%, compared with approximately 90% 
for notch-negative tumors. This notch pattern probably corresponds pathologically to the 
irregular edge of the invasive component.11 
 
 
 
Figure 14. Lepidic predominant adenocarcinoma. 
Axial CT image shows a part-solid nodule in the 
right upper lobe (arrow). This entity is 
characterized by a solid portion, corresponding 
histopathologically to overt (>5-mm) invasion, and 
also by a predominant nonsolid portion, 
corresponding histopathologically to a lepidic 
(non-invasive) pattern.  
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2.3.2 Invasive mucinous adenocarcinoma  
Another major change is the reclassification of the formerly mucinous BAC as “invasive 
mucinous adenocarcinoma” (Table IX). When multifocal (Figure 15) these mucinous tumors 
were formerly called multicentric BAC. They are distinguished from nonmucinous 
adenocarcinomas by mucinous tumor cell population consiting of tall columnar cells with 
abundant apical mucin and small basally oriented nuclei. While a lepidic pattern is common, 
most of these tumors have invasive components, and the tumors are often predominantly 
invasive. When these tumors are multifocal, they are often multilobar. The CT findings of this 
entity vary widely and include consolidations, air bronchograms, and multifocal and 
sometimes multilobar solid and subsolid (ie, either part-solid or nonsolid) nodules or masses, 
which tend to be centrilobular or bronchocentric. Lower lobe predominance is common for 
both the localized and multifocal forms of the disease11.  
Figure 15. Invasive mucinous adenocarcinoma. Axial CT images at (a) lung and (b) 
mediastinal window setting and (c) fluorine 18 fluorodeoxyglucose positron emission 
tomographic scan show fluorodeoxyglucose-avid tumor in the right lower lobe. When 
multifocal, this cancer was formerly called multicentric BAC. Microscopically, these 
adenocarcinomas contain abundant mucinous tumor cells, often a lepidic growth pattern, and 
are also often predomintly invasive. CT findings vary widely and include consolidations, air 
bronchograms, and multifocal and sometimes multilobar solid and nonsolid nodules or 
masses, which tend to be centrilobular or bronchocentric. Lower lobe predominance is 
common.  
a b c 
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2.3.3 CT technical considerations  
For optimal CT evaluation of subsolid pulmonary nodules, thin sections (< 3 mm thickness) 
are advisable. For malignant subsolid nodules, measuring an increase in attenuation at serial 
CT examinations appears to be less subject to variability than measures of diameter or 
volume. Quantitative volume histometric analysis of CT attenuation of nonsolid and part-solid 
nodules has been suggested as an approach to differentiating AAH (by a one-peak pattern of 
attenuation) from AIS and MIA (frequent two-peak pattern of attenuation) or frankly invasive 
adenocarcinoma (Figure 16). 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. AIS and lepidic predominant adenocarcinoma. Histograms, with the 
orizontal axis showing CT numbers in Hounsfield units and the vertical axis 
showing the volume proportion in the lesion, and CT images. Top left: Histogram 
with one peak of AIS. Top right: Corresponding CT image shows nonsolid nodule 
(arrowhead). Bottom left: Histogram with two peak for lepidic predominant 
adenocarcinoma (LPA). Bottom right: Corresponding CT image shows solid and 
nonsolid components (arrow).  
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Also, when subjective visual assessment of a nonsolid nodule at serial thin-section CT 
examinations suggests either possible but not definite enlargement of the nodule or possible 
but not definite development of a solid component, then increasing “mass” (mean volume 
multiplied by attenuation) may help identify early invasive growth, the increasing solid 
component corresponding to progression of local malignant invasion. For example, an 
increase of 100 HU in attenuation of a nonsolid nodule has been described recently as 
representing approximately 10% increase in tumor volume. These promising approaches need 
validation11.  
2.3.4 Size of the invasive component and prognosis 
An important aspect of adenocarcinomas of the lung is that, for small, solitary, early-stage 
tumors, the size of the invasive component-as measured histologically-is an independent 
predictor of survival. It is therefore attractive to consider that, for part-solid lesions evaluated 
by using CT for tumor size (T category of the TNM classification), the size of the solid 
portion may be more predictive of prognosis than total size that includes the nonsolid 
dimension. In support of this concept, a considerable literature has arisen for part-solid stage 
IA adenocarcinom of the lung, indicating that an extensive nonsolid component, which 
largely corresponds to a lepidic pattern of adenocarcinoma, is a favourable prognostic sign. 
Specifically, Sakao et al 12,13  have shown that, for small(< 20 mm) adenocarcinomas of the 
lung that are part-solid at CT, survival was a function of the diameter of the solid component, 
and not a function of a diameter that includes the nonsolid component. Hopefully, when the 
next (eight) edition of the TNM classification system is undergoing revision, further studies 
will have provided sufficient data to decide whether measuring tumor size (T status) should 
include only the solid component (or invasive component) of part solid (or part –lepidic or 
part-invasive) small, solitary lung adenocarcinomas. A recent multicenter study in Japan has 
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indicated that, for resected stage IA (T1N0M0) adenocarcinoma of the lung, disease-free 
survival did correlate with solid tumor size but not with “whole tumor size” that included a 
nonsolid (ground glass) component14. How exactly best to do the measurement (eg, by long 
axis, by mean value of long and short axes, or by semiautomated volumetry) and how to 
handle the occasional problem of multiple foci of a solid component remain as yet 
unanswered question11  .  
2.4 Follow-up and management of pulmonary nodules 
In 2005, recommendations for TC follow-up and management of small solid pulmonary 
nodules, mainly based on nodule size and patient’s risk profile (i.e. smoking history), were 
published as a statement from the Fleischner Society15 (Table X). 
 
 
A new report published in 2012 by the Fleischner Society complements the previous one 
dealing with the management of subsolid nodules 16 (Table XI).  
 
Table X. Recommendations for follow-up and management of nodules smaller than 8 mm 
detected incidentally at nonscreening CT. Note.-Newly detected indeterminate nodule in 
person 35 years of age or older.  *Average of length and width. † Minimal or absent 
history of smoking and of other known risk factors. ‡History of smoking or of other 
known risk factors. § The risk of malignancy in this category (<1%) is substantially less 
than that in a baseline CT scan of an asymptomatic smoker. ΙΙNonsolid (ground-glass) or 
partly solid nodules may require longer follow-up to exclude indolent adenocarcinoma.  
                                                                     
 
 37
 
Six specific recommendations were proposed, three regarding solitary subsolid nodules, and 
three regarding multiple subsolid nodules.  
 
The need for the development of a consensus regarding management of subsolid nodules is 
especially important given continued controversy about an optimal management strategy. 
 This is more urgent now that peripheral adenocarcinomas represent the most common type of 
lung cancer, ranging from 30% to 35% of all primary lung tumors, and with evidence of 
increasing frequency. 
Longer follow-up intervals are appropriate for nonsolid or part-solid nodules because subsolid 
malignant nodules have longer mean doubling times compared to solid malignant nodules.  
Solitary, pure GGNs measuring 5 mm or less do not require follow-up surveillance CT 
examination. 
Table XI. Recommendations for the management of subsolid pulmonary nodules detected at 
CT: a statement from the Fleischner Society.  
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Solitary, pure GGNs larger than 5 mm require an initial follow-up CT examination in 3 
months to determine persistence, followed by yearly surveillance CT examinations for a 
minimum of 3 years if persistent and unchanged.  
Solitary part-solid GGNs, especially those in which the solid component is larger than 5 mm, 
should be considered malignant until proved otherwise provided either growth or no change is 
seen at follow-up CT examination performed in 3 months.  
Multiple well-defined GGNs all measuring 5 mm or less should be conservatively managed 
with follow-up CT examinations performed at 2 and 4 years (Figure 17).  
 
 
 
 
 
Figure 17. Multiple GGNs smaller than 5mm. A-D, CT scans obtained with 1-
mm-thick sections show numerous scattered GGNs (arrows), all of which were 
smaller than 5 mm. Altough the likehood of any of these progressing to an 
invasive adenocarcinoma is likely no greater than that of a solitary lesion, 
consevative management is recommended, with follow-up CT examinations at 
2 and 4 years.  
 39
In cases in which multiple pure GGNs are identified, at least one of which is larger than 5 
mm, and in the absence of a dominant lesion, an initial follow-up CT examination in 3 months 
is recommended, followed by long-term yearly surveillance CT examinations for at least 3 
years (Figure 18). 
 
 
 
 
 
 
In cases with multiple subsolid nodules in which a dominant lesion(s) can be identified, the 
dominant lesion(s) determines further management. After an initial follow-up CT examination 
in 3 months that confirm persistence, an aggressive approach to diagnosis and management is 
recommended, especially for lesions with solid components larger than 5 mm16(Figure 19). 
Figure 18. Multiple GGNs lager than 5 mm in the absence of a dominant lesion. 
CT scans obtained with 1-mm-thick sections through right upper lobe (A) and 
lower lobes (B,C)  show three separate GGNs larger than 5 mm (arrows), all of 
approximately the same size. In the absence of a dominant lesion, conservative 
management with an initial follow-up examination in 3 months followed by 
yearly CT examination was recommended.  
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2.5 Role of Positron Emission Tomography (PET).  
Fluorodeoxyglucose positron emission tomography (FDG-PET) is commonly used for staging 
and follow-up of invasive adenocarcinoma, and of lesions suspect for adenocarcinoma of 7 
mm or larger.  Sensitivity of PET for AIS is usually very low. Elevated standard uptake 
values (SUVs) on PET  correlate  with cellular proliferation and aggressiveness of the primary 
cancer (Figure 20). SUV for adenocarcinoma of the lung tends to be lower than for other 
histologic types of lung cancer and correlate inversely with survival. PET may be more 
accurate than CT for assessing response to chemotherapy, although more studies are needed. 
 
Figure 19. Multiple subsolid lesions with single dominant focus. A-D, 
CT scans obtained with1-mm-thick  sections at same time in same patient 
show a variety of lesions (arrows) in both lungs. Lesion in middle lobe 
(A) is clearly larger and more complex than the others. Stage IA invasive 
lepidic adenocarcinoma was diagnosed at histologic examination of 
specimen from follow-up wedge resection.  
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For mucinous versus nonmucinous adenocarcinoma, after adjusting for size of the lesion, no 
significant difference in SUV has been found. For a small, well differentiated adenocarcinoma 
of low fluorodeoxyglucose avidity (e.g., maximum SUV<2,5) follow-up PET to assess 
change in SUV as a diagnostic tool unfortunately seems to be of only limited value1.  
 
 
 
 
 
 
 
 
 
 
 
 
2.6 Implications for treatment of new adenocarcinoma classification 
Especially  with the introduction of screenig programs in high-risk populations, there is a 
renewed interest in small nodules, especially those considered to be GGOs. Recent guidelines 
and a large, randomized screening trial conclude that small nodules <10 mm or <500mm3     
that are clearly 100% pure GGO lesions on chest CT and are suspected to be AIS or MIA 
pathologically, may be considered for close follow-up rather than immediate resection.  
The role of sublobar resection comprising anatomical segmentectomy and wedge excision to 
treat lung cancers <2cm, also remains controversial and is currently the subject of intensive 
Figure 20. CT and FDG-PET of invasive adenocarcinoma. A, Axial CT image 
and (B) FDG-PET  images show a 2-cm spiculated hypermetabolic solid nodule 
in the left lower lobe.   
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investigation. Many retrospective studies that are not randomized, suggest  that sublobar 
resection may be an adequate surgical treatment for early lung cancer. Most reports show no 
difference in survival or in locoregional recurrence between lobectomy and sublobar resection 
for tumors 2 cm or less in size. Patients with GGO tumors on CT have been reported to have a 
100% survival rate at 5 years after resection. However, possible delayed cut-end recurrences 
have been described after limited resection of GGO lesions.  
Two recent rewiews and one meta-analysis of sublobar resection concluded that sublobar 
resection, especially for pure AIS <2 cm, yields comparable survival and recurrence rates to 
lobectomy. In this way, sublobar resection is generally considered acceptable for GGO lesions 
or adenocarcinomas with minimal invasion. Lobectomy is still considered the standard 
surgical treatment for tumors 2 cm or less in size that have a solid apprearence on CT because 
such tumors are mostly invasive carcinomas. To make definite recommendations, the results 
two randomised trials (JCOG 0802 in Japan, CALGB 140503 in North America) randomising 
patients to either lobectomy or sublobar resection, are awaited for, although the latter trial 
excludes subsolid adenocarcinomas.2 
A specific treatment algorithm for lesions until 2 cm resulting from a prospective study has 
been proposed by Kodama et al.17 A retrospective study of a multicenter database of 502 
patients concluded that a systematic lymphadenectomy may not be necessary in solid tumors 
<8 mm on high-resolution chest CT or with a SUV max <1,5, even in cases of T1b tumors.18 
In a series of 94 pure solid stage T1a tumors, carcinoembryonic antigen (CEA) level and SUV 
max were significant predictors of lymph node involvement.19 Data from the European 
COSMOS screening trial show that systematic nodal dissection can be avoided in clinically 
N0 early stage lung cancers  when the pathological (not radiological!) size does not exceed 10 
mm or SUV max is < 2.0.  
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Regardless of the the extent of the resection, subclassification of NSCLC has significant 
treatment implications. The distinction between adenocarcinoma and squamous cell 
carcinoma is of major importance in the management of NSCLC as only patients with 
adenocarcinoma are eligible for tyrosine kinase inhibitor (TKI) therapy if the tumor harbors 
an EGFR mutation, or pemetrexed or bevacizumab-based chemotherapy regimen.  
As already mentioned, the micropapillary and solid pattern have a poorer prognosis compared 
to the other subtypes and more aggressive therapy seems warranted including lobectomy and 
probably adjuvant therapy to decrease the incidence of local and distant recurrences. In a 
study by Warth et al.20 patients with solid-predominant adenocarcinoma had a better 
prognosis when treated with adjuvant therapy. However, further randumized studies are 
necessary to make definite recommendations.AH (≤ 5 mm) 
 
3.1. Materials and methods 
Between June and December 2013, CT images of 93 patients that underwent CT examination 
of the lung were retrospectively retrieved and evaluated by using PACS systems by two 
radiologists.  
Fifty-one patients were male and 42 were female. Median age of the patients was 67,7 
years (age range 51-86 years). Concernig risk factors, 35 patients had a positive smoking 
history and a patient had a history of professional exposure to asbestosis.  
All CT examinations were performed by using a 64-channel CT ( LightSpeed VCT, General 
Electric) in the craniocaudal direction with inspiratory apnea. Vascular access was by a 
cubital vein with a 20-G needle. 
CT examinations protocol was the following: voltage of 120 kV, auto-mA (max 450 
mA), collimation of 2,5:2,5 mm; acquisition at baseline and after 40 and 70 seconds of delay 
 44
after iodinate contrast material intravenous administration. Signed informed consent was 
obtained from each patient for the use of contrast material after the evaluation of serum 
creatinine levels. 
Subsequently all nodular lesion underwent biopsy. All CT-guided biopsies were 
performed  percutaneously acquiring images of the chest for centering  with lung and 
mediastinal window setting by a high resolution 64-channels MDCT scanner (Discovery HD 
750, General Electric). At the time of the biopsy, selected images were obtained in the area of 
interest with 2,5 mm-thick contiguous sections. The scanning parameters were 120 kV and 
auto mA (max 450 mA). Patients were in supine or prone decubitus depending on the location 
of the lesion. The position allowed the easiest access route in order to avoid ribs, large 
vessels, emphysema, and interlobular fissures. 21 Gauge Chiba needles  were positioned 
under CT guidance in the context of the nodules for cytologic sampling, while 20 Gauge 
Biomol needles were used for cyto-histologic evaluation.  With the material aspired from each 
nodule a variable number of slides and a tube in 50% alcohol has been prepared; while for  
histology  samples a  tube  containing formalin was used. After the procedure another scan 
was performed to ascertain the presence of eventual complications (pneumothorax, local 
hemorrage). Small asymptomatic pneumothoraces were treated conservatively while a chest 
tube was inserted for drainage in patients with pneumothoraces associated with signs of 
shortness of breath or respiratory distress. Coagulation screening was performed before all 
procedures (exclusion criteria were prothrombin time <50% or a platelet count <50,000/µl). 
Prior to each procedure, the risks and benefits of were discussed, and signed informed consent 
was obtained from each patient. For each patient initials of the first name and surname, date 
of birth, date of the biopsy and the Pathological Anatomy Department of sending were 
registered.  
 45
By using a commercial PACS system (Esoate, Fujifilm), lesion size (measuring the 
maximum diameter of the lesion with electronic callipers), appearance of the nodule (ground 
glass opacity, solid nodule, part-solid nodule, mass, consolidation), location in the lung 
(which lobe involved and whether the nodule located centrally or peripherally in lung 
parenchyma) were evaluated on diagnostic CT images. The number of nodules, morphology 
of their margins (regular, irregular, lobulated or spiculated), and other nodule characteristics 
were also registered. 
The nodules that did noy undergo surgical resection were followed-up by CT. The 
nodules dimensional evolution in time was registered and classified in increase, stability or 
reduction with respect to the CT exams performed before the CT-guided biopsy. 
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3.3. Results 
The retrospective evaluation of CT examinations of the lung of the 93 patients performed  by 
using the PACS systems by two radiologist showed an overall number of 97 nodular lesions.  
According to the cytological and histological results of the nodules sampled, 38 nodular 
lesions resulted to be adenocarcinomas. In one case the biopsy was repeated because of 
material insufficient for a diagnosis. The remaining nodular lesions were excluded from our 
evaluation because of different hystotype (other lung malignancies such as primary lung 
cancers of other nature, lung metastases, inflammatory lesions, pleural nodules). Lung 
adenocarcinomas constituted 39 % of the total number of pulmonary malignant nodules 
biopsied and determined pathologically in the study period. Other lung malignancies excluded 
from the study were primary lung cancers (squamocellular carcinomas,  small cell 
carcinomas, large cell carcinomas, carcinoid tumors and others) and lung metastases 
(originating from colorectal cancer, pancreatic cancer and melanoma). 
Between the 38 lung adenocarcinoma considered, 33 samples (86,8%) were evaluated by 
the pathologists not only morphologically but also using immunoistochemical stains (TTF-1 
and Cytokeratyn 7 [CK-7] positivity and  p67 negativity were the most frequent findings). 
Molecular analysis was performed for two samples (one research  of EGFR mutation, that 
resulted positive and one research of ALK rearrangement, that resulted negative). In 3 cases 
both fine needle Aspirate (FNA) for cytological analysis and core biopsy for histological 
analysis were performed. 
The CT appearance of the 38 lung adenocarcinomas  are presented in table XII.  
The most frequent CT presentation was the solid nodule (14 cases, 36,8%). Other 
presentations were masses  (12 cases, 31,6%, in  2 cases a mass with a nonsolid component), 
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part-solid nodules (7 cases,  18,4%) and  consolidations (4 cases, 10,5%). One nodule was a 
ground-glass opacity  (2,6%).  
  
Table XII. CT findings of lung adenocarcinoma                  Number of lesions 
Ground glass opacity (GGO)                                  1 
Part-solid nodule                                  7 
Solid nodule                                 14 
Consolidation                                   4 
Mass                   12 (2 with a nonsolid component) 
 
Two cases were adenocarcinoma with mucinous differentiation as diagnosed by the 
pathologist. Their CT presentation was respectively consolidation and solid mass with a 
nonsolid component. Advanced cancers appeared as solid masses (lesions > 3 cm in major 
diameter). Concerning lesions size, the major diameter measured with electronic callipers was 
considered. The mean dimension of the lesions included was 33,8 mm (median value 30 mm, 
range 8-80 mm).  
Lesions were located in the pulmonary lobes equally without a preferential distribution (4 
in right upper lobe, 3 in middle lobe, 11 in right lower lobe , 14 in left upper lobe, 6 in left 
lower lobe). Adenocarcinomas in this pool of patients presented in form of solitary lesions in 
21 cases (55%). The remaining cases were multiple lesions probably because of the presence 
of synchronous cancers or metastases from the primitive lung cancer. 
Lesion margins were  irregular (35 cases, 92,1%) or spiculated in the remaining nodules.  
The location of the lesions in the lung was in the majority of cases peripheral (30 cases, 78,9 
%) and in rare cases central. Other possible associated characteristics of the nodules were 
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pleural retraction, pleural tags, bubble-like images or associated lymphangitis carcinomatosis.
  
N and M status of the tumors were not considered.  Examples of adenocarcinomas of the 
study pool presenting respectively as solid nodule, part-solid nodule and  mass are reported in 
Figures 21, 22 and 23.  
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Adenocarcinoma in the 
left lower lobe, presenting as part-
solid nodule.  
Figure 21. Adenocarcinoma of 
the right lower lobe, presenting 
as solid nodule.  
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In this study the new 2011 adenocarcinoma classification using radiological criteria was 
applied  to define lesions in the adenocarcinoma spectrum. AAH at imaging is a ground glass 
opacity of less than 5 mm. AIS is a small (<  3 cm) nonsolid opacity.  MIA is a part-solid 
nodule consisting of a predominant ground-glass component and a small (approximately < 5 
mm) central solid component. No nodules satisfied the radiological criteria to be considered 
AAH.  The only GGO satisfied criteria to be considered AIS (Figure 24). Two  part solid-
lesions satisfied the criteria to be considered MIA (Figure 25).  The other 35 lesions should be 
classified as invasive carcinoma, presenting as solid nodules, part-solid nodules, masses or 
consolidations.  
 
 
Figure 23. Mucinous 
adenocarcinoma in  the right lower 
lobe presenting as solid mass with a 
nonsolid component. 
Figure 24. 15 mm GGO in  the lower  
right lobe, representing AIS.  
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In Table XIII the results of the application of the new classification is showed.   
Table XIII. Application of the 2011 classification  of lung adenocarcinoma to the study pool 
AAH                        0 
AIS                    1 GGO 
                                 MIA                    2 part-solid nodules 
Invasive adenocarcinoma                    5 part-solid nodules,  
                  14 solid nodules, 
                    4 consolidations,  
                   12 masses 
 
Between the 38 adenocarcinoma nodules, fifteen underwent surgical intervention (10 
lobectomies, 2 segmentectomies and 3 atypical resections).  
Considering the chest CT exams performed before the CT-guided biopsy the dimensional 
evolution in time of 30 nodules  was in increase, while 8 nodules resulted stable.  
Figure 25. Part-solid nodule 
in the the left upper lobe, 
representing MIA.  
The lesion was treated with 
stereotactic radiotherapy.  
The patient had a history of 
right upper lobectomy for 
adenocarcinoma.  
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Between the seven part-solid adenocarcinoma nodules, in five cases an increase in the solid 
component as a sign of disease progression was observed. 
 
The 23 nodules that didn’t undergo surgical intervention were followed up by CT. Of these  
nodules, 9 reduced their dimensions, 2 remained stable and 2 increased their dimensions, 
mostly as a result of the chemoterapy and/or radiotherapy regimens followed by the patients. 
The follow-up CT exams of the remaining ten nodules were not found on our PACS system. 
Between the 15 nodules that underwent surgical resection, the 13 nodules classified as 
invasive adenocarcinomas by CT using radiological criteria, has been confirmed by the 
pathologist on surgical specimens (4 lepidic predominant adenocarcinomas, 3 papillary 
predominant adenocarcinomas, 2 acinar predominant adenocarcinomas, 2 scarcely 
differentiated adenocarcinomas, 1 solid predominant adenocarcinoma, 1 mucinous 
adenocarcinoma). Surgical resections performed for these invasive lesions has been: 
lobectomies (10), segmentectomies (2) and atypical resection (1). 
Also the remaining two nodules resected, one preinvasive lesion (AIS) and one minimally 
invasive lesion (MIA) as determined by CT, has been confirmed by the pathologist on 
surgical specimens. In both cases these nodules underwent atypical resection.  
3.4 Discussion. 
The new 2011 IASLC/ATS/ERS classification of adenocarcinoma of the lung introduces a 
number of new concepts that will have a major effect on CT evaluation of the disease.  
The recognition of preinvasive or minimally invasive lesions (AIS, MIA) is crucial because 
such nodules  should be considered for close follow-up rather than immediate resection.   
Moreover, sublobar resection rather than lobectomy is generally considered acceptable for 
GGO lesions or adenocarcinomas with minimal invasion. 
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In a part-solid adenocarcinoma the radiologist should measure both the solid and the nonsolid 
portion of the part-solid nodule: these components correspond respectively to the invasive and 
lepidic growth of the tumor and  their proportion is important in classifying such lesions in 
minimally invasive and overtly invasive tumors; nevertheless, overlap exists among the 
imaging features of the preinvasive and minimally invasive lesions in the lung 
adenocarcinoma spectrum.  Moreover in part-solid adenocarcinomas  the radiologist has to 
pay attention in the follow-up CT exams to detect an increase in the solid component as a sign 
of disease progression. CT over-estimates the effective size of invasive component at 
histopathology because the solid component at imaging includes fibrosis, alveolar collapse 
and mucus in addiction to cancer cells.  The size of the invasive component –as measured 
histologically-is an independent predictor of survival. So, for part-solid lesions evaluated by 
using CT for tumor size (T category in the TNM classification), the size of the solid portion 
may be more predictive of prognosis than total size that includes the nonsolid dimension.  
There is no consensus in how to make the measurement  (eg, by long axis, by mean value of 
long and short axes, or by semiautomated volumetry) and how to handle the occasional 
problem of multiple foci of solid component . 
In invasive adenocarcinomas pathologists have to consider the predominant histologic 
subtype (acinar, papillary, solid and lepidic)  after performing comprehensive histologic 
subtyping in which the percentage of each subtype is estimated in 5% increments.  
A fundamental advantage of the new classification is the disappearance of the confusing term 
Bronchioloalveolar Carcinoma (BAC), that now encompass a spectrum of terms (AAH, AIS, 
MIA, Lepidic Predominat Adenocarcinoma, Predominantly Invasive Adenocarcinoma, 
Invasive Mucinous  Adenocarcinoma) each of which has characteristic patterns of CT 
appearance.  
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A limitation of our retrospective study was the small sample size. A larger study population 
would have been desirable. However, a better application of the new 2011 lung 
adenocarcinoma classification both by the pathologists and the radiologists will allow an 
improved description of the lesions in the adenocarcinoma spectrum, from premalignant to 
frankly invasive lesions which necessitate different ways of management. 
3.5 Conclusion 
The present study demonstrates a good correlation between small biopsies/cytology, CT 
appearance and resection specimens in the lung adenocarcinoma spectrum by using the new 
2011  IASLC/ATS/ERS classification with radiological criteria. 
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